EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, BVAXF: Biovaxys Technology Corp

31 Oct 2025
LAST:

0.2021

CHANGE:
 0.00		OPEN:
0.1820		HIGH:
0.2048		ASK:
0.0000		VOLUME:
13.9K
CHG(%):
2.48		PREV:
0.1972		LOW:
0.1820		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
31 Oct 250.18200.20480.18200.202113.9K
30 Oct 250.17060.19800.16220.197251.2K
29 Oct 250.17380.17420.16000.169743.4K
28 Oct 250.18370.18440.17020.180950.8K
27 Oct 250.18560.20000.15000.150066.0K
24 Oct 250.19050.20000.18530.198035.3K
23 Oct 250.16420.19080.15890.187583.7K
22 Oct 250.16000.17400.15860.164811.7K
21 Oct 250.14460.16190.13860.1619263.3K
20 Oct 250.15650.19300.11790.1475346.4K

COMPANY PROFILE

Name:Biovaxys Technology Corp
About:BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
Sector:Healthcare
Industry:Biotechnology
Address:146 Thirtieth Street, Etobicoke, ON, Canada, M8W 3D4
Website:https://biovaxys.com
CIK:0001882559
ISIN:CA09076M1014
FIGI:BBG00MTP1T90

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.1812.3%
MA10:0.1814.8%
MA20:0.1625.4%
MA50:0.08161.4%
MA100:0.05287.2%
MA200:0.05346.1%
STO9:95.07 
STO14:75.31
RSI14:50.80
WPR14:-14.02 
MTM14:-0.01
ROC14:-0.04 
ATR:0.03 
Week High:0.201.3%
Week Low:0.1534.7%
Month High:0.229.4%
Month Low:0.12346.1%
Year High:0.229.4%
Year Low:0.011,265.5%
Volatility:188.12